Humulin M3 (30/70) Kwikpen (Insulin Human (Rdna))

Humulin M3 (30/70) Kwikpen is indicated for the management of blood glucose in adults with diabetes who require both basal and prandial insulin coverage.

• Type 1 diabetes mellitus requiring intensive insulin therapy.
• Type 2 diabetes mellitus inadequately controlled with oral agents or basal insulin alone.
• Situations where a fixed‑ratio premixed insulin simplifies dosing schedules.
• Patients transitioning from separate rapid‑acting and intermediate‑acting insulin injections to a single device.
• Use in hospital or outpatient settings where rapid dose adjustments are needed.
• Adults who prefer a prefilled pen to reduce injection steps and improve adherence.

• Humulin M3 (30/70) contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. The rapid‑acting component acts within minutes to lower post‑prandial glucose, while the protaminated intermediate component prolongs receptor stimulation, suppressing hepatic glucose production for up to 12–18 hours.

Adverse reactions to Humulin M3 (30/70) Kwikpen are reported in clinical practice and may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized fat loss or accumulation.
• Transient weight gain related to improved glycemic control.
• Nausea or gastrointestinal discomfort, often mild and transient.
• Dizziness or light‑headedness, usually related to low blood glucose.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms requiring assistance.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Edema or fluid retention, particularly in patients with cardiac or renal impairment.

When prescribing or using Humulin M3 (30/70) Kwikpen, clinicians and patients should consider several safety precautions to minimize risks.

• Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance.
• Adjust doses in elderly or frail patients to reduce hypoglycemia risk.
• Counsel patients on recognizing and treating hypoglycemia promptly.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Monitor blood glucose regularly, especially during periods of illness, stress, or changes in diet or activity.
• Consider pregnancy status; insulin requirements may change and close monitoring is essential.

Humulin M3 (30/70) Kwikpen may interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins or concentrated insulin formulations without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, making detection difficult.
• Corticosteroids or other agents that markedly raise blood glucose, potentially requiring higher insulin doses.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity and lower glucose.
• Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.